AMSTERDAM and IRVINE, Calif., May 29, 2012 \/PRNewswire\/ --Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that it will present nine posters on genomic research studies in breast and colon cancer at the Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held from June 1-5, 2012, at McCormick Place in Chicago, IL. <\/p>\n
Currently on the market in the U.S. and Europe, Agendia's Symphony suite of molecular diagnostic breast cancer tests enables physicians to determine whether a given breast cancer patient is likely to benefit from hormonal therapy, chemotherapy and targeted therapies, thereby providing benefits over existing treatment approaches for patients, physicians and payers. <\/p>\n
Agendia's lead product, MammaPrint, is the first and only diagnostic breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). Agendia's product development pipeline includes a further extension of its breast cancer tests as well as similar molecular diagnostic products for colon cancer. <\/p>\n
All of the abstracts listed below can currently be found online at http:\/\/www.ASCO.org<\/a>. Presentation details are as follows (all times are in Central Time). <\/p>\n Friday, June 1, 2012 <\/p>\n Colorectal Cancer <\/p>\n 1. Poster Presentation & Discussion: Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients. <\/p>\n Saturday, June 2, 2012 <\/p>\n Breast Cancer <\/p>\n 2. Poster Presentation: Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U.S. breast cancer (BC) patients. <\/p>\n<\/p>\n Read the original here: <\/p>\n Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" AMSTERDAM and IRVINE, Calif., May 29, 2012 \/PRNewswire\/ --Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that it will present nine posters on genomic research studies in breast and colon cancer at the Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held from June 1-5, 2012, at McCormick Place in Chicago, IL. Currently on the market in the U.S Continue reading